StockWatch
·

Lyell Immunopharma, Inc. Q2 FY26 Results

LYELQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue0.00100.0%
Total Income0.00100.0%
Expenditure47.347.0%0.4%
PBT—
Net Profit-44.7685.3%4.9%
OPM—
NPM—
EPS-1.9274.5%33.6%
View full financials

Lyell Immunopharma Reports Q2 2026 Net Loss of $44.8 Million Amidst Clinical Progress

07 Aug 2026 · 7 Aug, 1:55 am

Summary

Lyell Immunopharma reported a net loss of $44.8 million for the second quarter ended June 30, 2026, an increase from $42.7 million in the same period last year, primarily driven by a $4.7 million rise in research and development expenses due to heightened clinical trial activity. The company's financial position remains robust with $228.0 million in cash, cash equivalents, and marketable securities, providing a projected cash runway into the third quarter of 2027. Significant clinical progress was highlighted, including the PiNACLE pivotal trial for ronde-cel remaining on track for additional data in late 2026 and a BLA submission in late 2027. Additionally, updated safety data for LYL273 showed a substantial reduction in adverse events, leading to an amendment of its U.S. Phase 1 trial to a Phase 1/2 design for potential pivotal expansion.

Key Highlights

  1. 1

    Lyell Immunopharma reported a net loss of $44.8 million for the second quarter ended June 30, 2026, compared to a net loss of $42.7 million for the same period in 2025.

  2. 2

    Research and development expenses increased by $4.7 million to $39.5 million in Q2 2026, primarily driven by increased clinical trial activity.

  3. 3

    The company's cash, cash equivalents, and marketable securities totaled $228.0 million as of June 30, 2026, providing a projected runway into the third quarter of 2027.

  4. 4

    The PiNACLE pivotal clinical trial for ronde-cel is on track to report additional data in the second half of 2026, with pivotal data expected mid-2027 and BLA submission in the second half of 2027.

  5. 5

    Updated LYL273 safety data showed a significant reduction in Grade ≥ 2 diarrhea or colitis from 55% to 10% with a new gastrointestinal prophylaxis regimen.

  6. 6

    The U.S. Phase 1 trial for LYL273 was amended to a Phase 1/2 design, enabling seamless expansion into a potential pivotal single-arm Phase 2 trial.

Informational and educational content only. Not investment advice.